080223_CCL_CME_HoFH_CME_Info






Global Logo
PQH Logo
HoFH: Achieving Earlier Diagnosis and Optimizing Outcomes Using Non‐statin Therapies

This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with American Society for Preventive Cardiology (ASPC).

ACKNOWLEDGEMENT

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

DATE OF RELEASE/EXPIRATION

This activity was released on August 2, 2023 and is valid for 12 months. Requests for credit must be made no later than August 2, 2024.

TARGET AUDIENCE

The educational design of this activity addresses the needs of cardiologists, endocrinologists, and primary care practitioners.

STATEMENT OF NEED/PROGRAM OVERVIEW

Establishing an early diagnosis of homozygous familial hypercholesterolemia (HoFH) is important to promptly initiate treatment and lower low‐density lipoprotein cholesterol (LDL‐C) and risk of progressive atherosclerotic cardiovascular disease. HoFH is a difficult‐to‐treat disorder with most patients requiring multiple lipid-lowering therapies and many not achieving target LDL‐C levels. 

Join an expert panel of cardiologists and lipidologists to review recommended screening and diagnostic techniques for HoFH. Clinicians will learn about new therapies and indications, including selection and sequencing of HoFH treatments. Panelists will also share proven patient-communication techniques to enhance shared decision-making and align HCP and patient perspectives and goals. 

Do you have patients at risk for or with HoFH who could use education on effective screening, treatments, and coping strategies? Direct your patients to MedLive.com to access the activity, “Navigating HoFH: Understanding Your Diagnosis and Treatment Options and Working with the Care Team.”

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:

  • Identify recommended screening approaches and diagnostic criteria for HoFH
  • Discuss strategies for incorporating therapies for HoFH into a patient‐centered treatment plan
  • Describe the mechanisms of action and efficacy and safety data for newer agents for HoFH, including emerging indications

PHYSICIAN ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION

Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 1 hour to complete.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is no fee for this educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Name of Faculty or Presenter Reported Financial Relationship
Seth Martin, MD, MHS, FAHA, FACC, FASPC
Professor of Medicine
Director of the Advanced Lipid Disorders Program and Digital Health Lab, Ciccarone Center for the Prevention of Cardiovascular Disease
Johns Hopkins School of Medicine
Consulting Fee (e.g., Advisory Board): AstraZeneca, Amgen, NewAmsterdam Pharma, Novartis, Premier
Contracted Research (Principal Investigators must provide information, even if received by the institution): Merck
Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA
Professor of Medicine, Cardiology
Paul V. Kramer Endowed Chair in Cardiovascular Disease Prevention
Director, Seinsheimer Cardiovascular Health Program
Trustee, American College of Cardiology
The Medical University of South Carolina
Contracted Research (Principal Investigators must provide information, even if received by the institution): Esperion

The planners and managers at Global Education Group have no relevant financial relationships to disclose. 

The planners and managers at PlatformQ Health Education have no relevant financial relationships to disclose.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support:

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com

Technical Support:

For any technical issues or issues with your CME Certificate, please contact CardioCareLive at 877-394-1306 or at Support@CardioCareLive.com.